Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

Jean Pierre Lindenmayer, Pal Czobor, Jan Volavka, Leslie Citrome, Brian Sheitman, Joseph Patrick McEvoy, Thomas B. Cooper, Miranda Chakos, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

431 Citations (Scopus)

Abstract

Objective: The association of hyperglycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case reports and uncontrolled studies. The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. Method: One hundred fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hospi3 tals were originally included in the study. The 14-week trial consisted of an 8-week fixed-dose period and a 6-week variable-dose period. Planned assessments included fasting glucose and cholesterol, which were collected at baseline and at the end of the 8-week period and the following 6-week period. Results: One hundred eight of the 157 patients provided blood samples at baseline and at least at one point after random assignment to clozapine, olanzapine, risperidone, or haloperidol during the treatment trial. Seven of these patients had diabetes; their glucose levels were >125 mg/dl at baseline. Data from 101 patients were used for statistical analyses. During the initial 8-week period there was an overall significant increase in mean glucose levels. There were significant increases in glucose levels at the end of the 8-week fixed-dose period for patients given clozapine (N=27) and those given haloperidol (N=25). The olanzapine group showed a significant increase of glucose levels at the end of the 6-week variable-dose period (N=22). Fourteen of the 101 patients developed abnormal glucose levels (>125 mg/dl) during the trial (six with clozapine, four with olanzapine, three with risperidone, and one with haloperidol). Cholesterol levels were increased at the end of the 8-week fixed-dose period for the patients given clozapine (N=27) and those given olanzapine (N=26); cholesterol levels were also increased at the end of the 6-week variable-dose period for patients given olanzapine (N=22). Conclusions: In this prospective randomized trial, clozapine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanzapine were associated with an increase in cholesterol levels. The mean changes in glucose and cholesterol levels remained within clinically normal ranges, but approximately 14% of the patients developed abnormally high glucose levels during the course of their participation in the study.

Original languageEnglish (US)
Pages (from-to)290-296
Number of pages7
JournalAmerican Journal of Psychiatry
Volume160
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

olanzapine
Antipsychotic Agents
Schizophrenia
Clozapine
Cholesterol
Glucose
Haloperidol
Risperidone
Psychotic Disorders
Hypercholesterolemia
Hyperglycemia
Inpatients
Fasting

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. / Lindenmayer, Jean Pierre; Czobor, Pal; Volavka, Jan; Citrome, Leslie; Sheitman, Brian; McEvoy, Joseph Patrick; Cooper, Thomas B.; Chakos, Miranda; Lieberman, Jeffrey A.

In: American Journal of Psychiatry, Vol. 160, No. 2, 01.02.2003, p. 290-296.

Research output: Contribution to journalArticle

Lindenmayer, JP, Czobor, P, Volavka, J, Citrome, L, Sheitman, B, McEvoy, JP, Cooper, TB, Chakos, M & Lieberman, JA 2003, 'Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics', American Journal of Psychiatry, vol. 160, no. 2, pp. 290-296. https://doi.org/10.1176/appi.ajp.160.2.290
Lindenmayer, Jean Pierre ; Czobor, Pal ; Volavka, Jan ; Citrome, Leslie ; Sheitman, Brian ; McEvoy, Joseph Patrick ; Cooper, Thomas B. ; Chakos, Miranda ; Lieberman, Jeffrey A. / Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. In: American Journal of Psychiatry. 2003 ; Vol. 160, No. 2. pp. 290-296.
@article{d60b9d0ed4c846c5bd0917cdb92382d2,
title = "Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics",
abstract = "Objective: The association of hyperglycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case reports and uncontrolled studies. The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. Method: One hundred fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hospi3 tals were originally included in the study. The 14-week trial consisted of an 8-week fixed-dose period and a 6-week variable-dose period. Planned assessments included fasting glucose and cholesterol, which were collected at baseline and at the end of the 8-week period and the following 6-week period. Results: One hundred eight of the 157 patients provided blood samples at baseline and at least at one point after random assignment to clozapine, olanzapine, risperidone, or haloperidol during the treatment trial. Seven of these patients had diabetes; their glucose levels were >125 mg/dl at baseline. Data from 101 patients were used for statistical analyses. During the initial 8-week period there was an overall significant increase in mean glucose levels. There were significant increases in glucose levels at the end of the 8-week fixed-dose period for patients given clozapine (N=27) and those given haloperidol (N=25). The olanzapine group showed a significant increase of glucose levels at the end of the 6-week variable-dose period (N=22). Fourteen of the 101 patients developed abnormal glucose levels (>125 mg/dl) during the trial (six with clozapine, four with olanzapine, three with risperidone, and one with haloperidol). Cholesterol levels were increased at the end of the 8-week fixed-dose period for the patients given clozapine (N=27) and those given olanzapine (N=26); cholesterol levels were also increased at the end of the 6-week variable-dose period for patients given olanzapine (N=22). Conclusions: In this prospective randomized trial, clozapine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanzapine were associated with an increase in cholesterol levels. The mean changes in glucose and cholesterol levels remained within clinically normal ranges, but approximately 14{\%} of the patients developed abnormally high glucose levels during the course of their participation in the study.",
author = "Lindenmayer, {Jean Pierre} and Pal Czobor and Jan Volavka and Leslie Citrome and Brian Sheitman and McEvoy, {Joseph Patrick} and Cooper, {Thomas B.} and Miranda Chakos and Lieberman, {Jeffrey A.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1176/appi.ajp.160.2.290",
language = "English (US)",
volume = "160",
pages = "290--296",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

AU - Lindenmayer, Jean Pierre

AU - Czobor, Pal

AU - Volavka, Jan

AU - Citrome, Leslie

AU - Sheitman, Brian

AU - McEvoy, Joseph Patrick

AU - Cooper, Thomas B.

AU - Chakos, Miranda

AU - Lieberman, Jeffrey A.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Objective: The association of hyperglycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case reports and uncontrolled studies. The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. Method: One hundred fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hospi3 tals were originally included in the study. The 14-week trial consisted of an 8-week fixed-dose period and a 6-week variable-dose period. Planned assessments included fasting glucose and cholesterol, which were collected at baseline and at the end of the 8-week period and the following 6-week period. Results: One hundred eight of the 157 patients provided blood samples at baseline and at least at one point after random assignment to clozapine, olanzapine, risperidone, or haloperidol during the treatment trial. Seven of these patients had diabetes; their glucose levels were >125 mg/dl at baseline. Data from 101 patients were used for statistical analyses. During the initial 8-week period there was an overall significant increase in mean glucose levels. There were significant increases in glucose levels at the end of the 8-week fixed-dose period for patients given clozapine (N=27) and those given haloperidol (N=25). The olanzapine group showed a significant increase of glucose levels at the end of the 6-week variable-dose period (N=22). Fourteen of the 101 patients developed abnormal glucose levels (>125 mg/dl) during the trial (six with clozapine, four with olanzapine, three with risperidone, and one with haloperidol). Cholesterol levels were increased at the end of the 8-week fixed-dose period for the patients given clozapine (N=27) and those given olanzapine (N=26); cholesterol levels were also increased at the end of the 6-week variable-dose period for patients given olanzapine (N=22). Conclusions: In this prospective randomized trial, clozapine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanzapine were associated with an increase in cholesterol levels. The mean changes in glucose and cholesterol levels remained within clinically normal ranges, but approximately 14% of the patients developed abnormally high glucose levels during the course of their participation in the study.

AB - Objective: The association of hyperglycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case reports and uncontrolled studies. The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. Method: One hundred fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hospi3 tals were originally included in the study. The 14-week trial consisted of an 8-week fixed-dose period and a 6-week variable-dose period. Planned assessments included fasting glucose and cholesterol, which were collected at baseline and at the end of the 8-week period and the following 6-week period. Results: One hundred eight of the 157 patients provided blood samples at baseline and at least at one point after random assignment to clozapine, olanzapine, risperidone, or haloperidol during the treatment trial. Seven of these patients had diabetes; their glucose levels were >125 mg/dl at baseline. Data from 101 patients were used for statistical analyses. During the initial 8-week period there was an overall significant increase in mean glucose levels. There were significant increases in glucose levels at the end of the 8-week fixed-dose period for patients given clozapine (N=27) and those given haloperidol (N=25). The olanzapine group showed a significant increase of glucose levels at the end of the 6-week variable-dose period (N=22). Fourteen of the 101 patients developed abnormal glucose levels (>125 mg/dl) during the trial (six with clozapine, four with olanzapine, three with risperidone, and one with haloperidol). Cholesterol levels were increased at the end of the 8-week fixed-dose period for the patients given clozapine (N=27) and those given olanzapine (N=26); cholesterol levels were also increased at the end of the 6-week variable-dose period for patients given olanzapine (N=22). Conclusions: In this prospective randomized trial, clozapine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanzapine were associated with an increase in cholesterol levels. The mean changes in glucose and cholesterol levels remained within clinically normal ranges, but approximately 14% of the patients developed abnormally high glucose levels during the course of their participation in the study.

UR - http://www.scopus.com/inward/record.url?scp=0037315939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037315939&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.160.2.290

DO - 10.1176/appi.ajp.160.2.290

M3 - Article

C2 - 12562575

AN - SCOPUS:0037315939

VL - 160

SP - 290

EP - 296

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -